MedPath

BMS-986141

Generic Name
BMS-986141
Drug Type
Small Molecule
Chemical Formula
C27H23N5O5S2
CAS Number
1478711-48-6
Unique Ingredient Identifier
W530IRZ40G
Background

BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).

Clinical Trials
Related News

A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants

Phase 2
Completed
Conditions
Coronary Artery Disease
Healthy Participants
Interventions
First Posted Date
2021-10-26
Last Posted Date
2023-12-05
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
58
Registration Number
NCT05093790
Locations
πŸ‡¬πŸ‡§

Local Institution - 0001, Edinburgh, United Kingdom

Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants

First Posted Date
2017-01-30
Last Posted Date
2018-03-23
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT03035734

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Phase 1
Withdrawn
Conditions
Hepatic Impairment
Interventions
First Posted Date
2016-12-07
Last Posted Date
2017-02-06
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT02985632
Locations
πŸ‡ΊπŸ‡Έ

Clinical Pharmacology of Miami, Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

Texas Liver Institute, San Antonio, Texas, United States

πŸ‡ΊπŸ‡Έ

Clinical Research Center, Orlando, Florida, United States

A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects

Phase 1
Completed
Conditions
Atherothrombotic Diseases
Interventions
First Posted Date
2016-11-06
Last Posted Date
2017-02-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
16
Registration Number
NCT02957448

A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects

Phase 1
Completed
Conditions
Ischemic Stroke
Interventions
Drug: Dilitazem
First Posted Date
2016-10-04
Last Posted Date
2016-12-20
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
16
Registration Number
NCT02922452
Locations
πŸ‡ΊπŸ‡Έ

PPD Development, Austin, Texas, United States

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Phase 2
Completed
Conditions
Thrombosis
Interventions
Other: Placebo
First Posted Date
2016-02-02
Last Posted Date
2018-12-14
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
16
Registration Number
NCT02671461
Locations
πŸ‡ΊπŸ‡Έ

York Hospital, York, Pennsylvania, United States

πŸ‡ΊπŸ‡Έ

Boston Medical Center, Boston, Massachusetts, United States

πŸ‡ΊπŸ‡Έ

Duke University Medical Center, Durham, North Carolina, United States

and more 20 locations

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

Phase 1
Completed
Conditions
Thrombosis
Interventions
Drug: Placebo
First Posted Date
2015-01-19
Last Posted Date
2017-03-31
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
148
Registration Number
NCT02341638
Locations
πŸ‡ΊπŸ‡Έ

West Coast Clinical Trials, Llc, Cypress, California, United States

πŸ‡ΊπŸ‡Έ

Ppd Development, Lp, Austin, Texas, United States

Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy